www.turner-white.com Oncology Volume 10, Part 2 19
trial of temozolomide in patients with anaplastic astrocytoma
or anaplastic oligoastrocytoma at first relapse. Temodal
Brain Tumor Group. J Clin Oncol 1999;17:2762–71.
43. Chheda MG, Drappatz J, Greenberger NJ, et al. Hepatitis
B reactivation during glioblastoma treatment with temozolomide: a cautionary note. Neurology 2007;68:955–6.
44. Grewal J, Dellinger CA, Yung WK. Fatal reactivation of hepatitis B with temozolomide. N Engl J Med 2007;356:1591–2.
45. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic
predictors of chemotherapeutic response and survival in
patients with anaplastic oligodendrogliomas. J Natl Cancer
Inst 1998;90:1473–9.
46. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy
alone for pure and mixed anaplastic oligodendroglioma:
Intergroup Radiation Therapy Oncology Group Trial 9402. J
Clin Oncol 2006;24:2707–14.
47. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant
procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term
follow-up of EORTC brain tumor group study 26951. J Clin
Oncol 2013;31:344–50.
48. Cairncross G, Wang M, Shaw E, et al. Phase III trial of
chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31:337–43.
49. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly
diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol
2006;24:2715–22.
50. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl
J Med 2005;352:997–1003.
51. Ruano Y, Mollejo M, Ribalta T, et al. Identification of novel
candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray
profiling. Mol Cancer 2006;5:39.
52. De Witt Hamer PC. Small molecule kinase inhibitors in
glioblastoma: a systematic review of clinical studies. Neuro
Oncol 2010;12:304–16.
53. Lassman AB, Holland EC. Incorporating molecular tools into
clinical trials and treatment for gliomas? Curr Opin Neurol
2007;20:708–11.
54. Sampson JH, Aldalpe K, Gilbert MR, et al. Temozolomide
as a vaccine adjuvant in GBM [ASCO abstract 2020]. J Clin
Oncol 2007;25(18S).
55. Freeman AI, Zakay-Rones Z, Gomori JM, et al. Phase I/
II trial of intravenous NDV-HUJ oncolytic virus in recurrent
glioblastoma multiforme. Mol Ther 2006;13:221–8.
56. Chiocca EA, Abbed KM, Tatter S, et al. A phase I open-label,
dose-escalation, multi-institutional trial of injection with an
E1B-Attenuated adenovirus, ONYX-015, into the peritu-moral region of recurrent malignant gliomas, in the adjuvant
setting. Mol Ther 2004;10:958–66.
57. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell
vaccination in glioblastoma patients induces systemic and
intracranial T-cell responses modulated by the local central
nervous system tumor microenvironment. Clin Cancer Res
2005;11:5515–25.
58. Cohen AL, Holmen SL, Colman H. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 2013;13:345.
59. Phillips HS, Kharbanda S, Chen R, et al. Molecular sub-classes of high-grade glioma predict prognosis, delineate
a pattern of disease progression, and resemble stages in
neurogenesis. Cancer Cell 2006;9:157–73.
60. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1,
EGFR, and NF1. Cancer Cell 2010;17:98–110.
61. Chamberlain MC, Glantz MJ, Chalmers L, et al. Early necrosis following concurrent Temodar and radiotherapy in
patients with glioblastoma. J Neurooncol 2007;82:81–3.
62. de Wit MC, de Bruin HG, Eijkenboom W, et al. Immediate
post-radiotherapy changes in malignant glioma can mimic
tumor progression. Neurology 2004;63:535–7.
63. Taal W, Brandsma D, de Bruin H, et al. The incidence of
pseudo-progression in a cohort of malignant glioma patients
treated with chemo-radiation with temozolomide [ASCO abstract 2009]. J Clin Oncol 2007;25(18S).
64. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter
methylation status can predict the incidence and outcome
of pseudoprogression after concomitant radiochemotherapy
in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26:2192–7.
65. Giglio P, Gilbert MR. Cerebral radiation necrosis. Neurologist 2003;9:180– 8.
66. Levin VA, Bidaut L, Hou P et al. Randomized double-blind
placebo-controlled trial of bevacizumab therapy for radiation
necrosis of the central nervous system. Int J Radiat Oncol
Biol Phys 2011;79:1487–95.
67. Caine C, Mehta MP, Laack NN, Gondi V. Cognitive function
testing in adult brain tumor trials: lessons from a comprehensive review. Expert Rev Anticancer Ther 2012;12:655–67.
68. Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function
of brain tumor patients. J Clin Oncol 1998;16:2522–7.
69. Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk
of thromboembolism during treatment high-grade gliomas: a
prospective study. Eur J Cancer 1997;33:1592–6.
70. Sawaya R, Zuccarrello M, Elkalliny M, Nishiyama H. Postop-
